title: Association of genetic variants in CYP2C19 and adverse clinical outcomes after treatment with clopidogrel: an updated meta-analysis.
authors.forename: Yan Ping
authors.initials: YP
authors.lastname: Liu
authors.forename: Pan Pan
authors.initials: PP
authors.lastname: Hao
authors.forename: Ming Xiang
authors.initials: MX
authors.lastname: Zhang
authors.forename: Cheng
authors.initials: C
authors.lastname: Zhang
authors.forename: Fei
authors.initials: F
authors.lastname: Gao
authors.forename: Yun
authors.initials: Y
authors.lastname: Zhang
authors.forename: Yu Guo
authors.initials: YG
authors.lastname: Chen
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D000077144:Clopidogrel; D065731:Cytochrome P-450 CYP2C19; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D013988:Ticlopidine